We examined the epidemiological associations between serum fructosamine and dyslipidemia indices in community-dwelling adults. Clinical characteristics and lipid profiles were analyzed in 1352 community-dwelling adults. The demographic characteristics and laboratory results were grouped according to the quartiles of serum fructosamine concentrations in all eligible individuals. From the bottom to the top quartile of serum fructosamine, there were graded increases in age, total cholesterol (TC), fasting blood glucose (FBG), total protein (TP), triglyceride (TG), total cholesterol/ high density lipoprotein-cholesterol (TC/HDL-C) and atherogenic index of plasma (AIP). Serum fructosamine was positive correlated with age, TC, FBG, TP, TG, TC/HDL-C and AIP in whole individuals. The positive correlations were then observed in both genders between serum fructosamine and TC, FBG, TP, TG. Two dominant factors were identified by principal component analysis. Logistic regression analysis showed that the two factors were associated with increased serum fructosamine with adjustment for gender, age, body mass index (BMI), FBG and TP. The similar results were observed in males, but not in females. Dyslipidemia tends to contribute to increased serum fructosamine concentrations in study population, suggesting that elevated serum fructosamine may herald an increased risk of cardiovascular disease among community-dwelling adults, especially in males.
The morbidity and mortality of cardiovascular disease are universal global events and are major challenges for public health, especially in developing countries1. Cardiovascular disease has been reported to be one of the most common and momentous public health crises worldwide2. The morbidity of cardiovascular disease accounts for approximately 66% in all disease diagnosis3. Serum fructosamine is a glycated protein to reflect average glycemia over the previous 2–3 weeks, and is considered to be a simple and inexpensive measure for the estimation of short to medium-term alteration in blood glucose concentrations4. Peng et al.5 reported a positive correlation between serum fructosamine and estimated glomerular filtration rate in non-diabetic individuals. Previous studies have demonstrated that higher serum fructosamine levels were associated with coronary artery atherosclerosis, dementia and renal failure6,7,8,9. Very recently, serum fructosamine has been found to be an independently predictor of vascular outcomes10. Accumulating data have shown that serum fructosamine is prospectively associated with risk of morbidity and mortality of cardiovascular disease in both diabetic and non-diabetic patients11, 12. Knowing that dyslipidemia is associated with significantly increased risk of cardiovascular disease. Up to our knowledge, the associations of serum fructosamine with lipid profiles in healthy population have been discussed poorly. In addition, serum fructosamine that serves as a reliable and indirect index to reflect lipid profiles may be valuable in healthy population. Therefore, we examined the epidemiological relationships between serum fructosamine and lipid profiles in community-dwelling adults.
Materials and Methods
A total of 1352 community-dwelling adults who underwent routine physical examinations in Affiliated Hospital of Youjiang Medical University for Nationalities between January 2015 and January 2016 were included in this cross-sectional study. All individuals were examined by general practitioners for physical examinations. Baseline demographics and medical history were obtained from medical-record department. Healthy individuals without hypertension, diabetes and stroke were eligible in our study. Additional exclusion criteria included known history of cardiovascular disease such as myocardial infarction, angina, coronary arterial disease, heart failure and atrial fibrillation. Moreover, individuals who contracted podagra, abnormal hepatic or renal function, infectious disease, autoimmune disease, malignant tumor, anemia, psychosis and pregnancy were also excluded. The research was executed on based of the Declaration of Helsinki, and all procedures were approved by the Ethics Committee of Affiliated Hospital of Youjiang Medical University for Nationalities, and informed consent was obtained in all participants.
Fasting venous blood samples were analyzed in clinical laboratory. Values of total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), triglyceride (TG), fasting blood glucose (FBG), total protein (TP), and fructosamine were measured within 2 h after admission. Atherogenic index of plasma (AIP) was used to estimate a potential risk of atherosclerosis, the equation was log (TG/HDL-C)13. Weight and height were measured in all participants, and body mass index (BMI) was calculated by dividing weight in kilograms by height in meters squared (kg/m2). Plasma lipids were assayed by enzymatic methods, serum fructosamine was assayed by nitro blue tetrazolium chloride methods on automatic biochemical analyzer.
Our data were analyzed by SPSS16.0 (SPSS Inc, Chicago, IL, USA) statistical software for statistical analysis. Continuous variables were shown as mean ± standard deviation, and categorical variables were presented as percentages. Chi-square test and one-way ANOVA test were used to examine differences in continuous and categorical variables. The correlations between the two continuous variables were analyzed using Spearman approach. Principal components analysis was used to determine factor loadings. The factor scores were considered as independent variable in logistic regression analysis. P < 0.05 was determined as significant.
Demographic characteristics and lipid profiles were analyzed in community-dwelling adults. The demographic characteristics and laboratory results were grouped according to the quartiles of serum fructosamine concentrations in all eligible individuals, as shown in Table 1. Mean values of TC, LDL-C, HDL-C, TG, TP, FBG, AIP and fructosamine were 4.8 ± 1.02 mmol/L, 2.5 ± 0.99 mmol/L, 1.4 ± 0.34 mmol/L, 1.8 ± 1.48 mmol/L, 72.0 ± 4.68 g/L, 5.1 ± 0.62 mmol/L, 0.06 ± 0.31% and 2.0 ± 0.35 mmol/L in all eligible individuals, respectively. From the bottom to the top quartile of serum fructosamine, there were graded increases in age, TC, FBG, TP, TG, TC/HDL-C and AIP.
The results of analysis on the correlations between serum fructosamine and lipid profiles showed that serum fructosamine was positive correlated with age (r = 0.090, P = 0.001), TC (r = 0.172, P < 0.001), FBG (r = 0.115, P < 0.001), TP (r = 0.112, P < 0.001), TG (r = 0.143, P < 0.001), TC/HDL-C (r = 0.106, P < 0.001) and AIP (r = 0.110, P < 0.001) in whole individuals. The positive correlations were then observed in both genders between serum fructosamine and TC (r = 0.155, P < 0.001 in males; r = 0.229, P < 0.001 in females), FBG (r = 0.118, P < 0.001 in males; r = 0.128, P = 0.025 in females), TP (r = 0.087, P = 0.005 in males; r = 0.195, P < 0.001 in females), TG (r = 0.150, P < 0.001 in males; r = 0.159, P = 0.005 in females). In addition, serum fructosamine was found to be positive correlated with AIP (r = 0.131, P < 0.001) in males.
To identify the main contributors of the lipid profiles for serum fructosamine levels in the study population, the lipid variables (TC, LDL-C, HDL-C, TG, TC/HDL-C, AIP) were investigated by principal component analysis with varimax (orthogonal) rotation. The lipid variables were combined into factors, two dominant factors were identified by principal component analysis, subsequently named the “AIP” pattern (factor 1) and the “LDL-C” pattern (factor 2), as shown in Table 2, the total variance was explained by the two factors was 82.4%. Individual factor scores were obtained for each pattern by summing the original lipid variables multiplied by their factor loadings. To investigate the relationships between the two patterns (factor 1 and factor 2) and serum fructosamine, the two factor scores were considered as independent variable in the logistic regression model predicting serum fructosamine levels. Logistic regression analysis showed that the two factors were associated with increased serum fructosamine with adjustment for gender, age, BMI, FBG and TP, the resulting odds ratio (OR) and 95% confidence interval (95% CI) of fourth vs first quartile of serum fructosamine were 1.676 (95% CI: 1.405–1.999, P < 0.001) for factor 1, 1.266 (95% CI: 1.070–1.499, P = 0.006) for factor 2 (Table 3).
Since physiological characteristics are different between females and males, so that we decided to separate the population into genders for further statistical analysis. In male individuals (fourth vs first quartile of serum fructosamine as dependent variable), the two factors were found to be independently associated with serum fructosamine in logistic regression analysis (OR = 1.804, 95% CI: 1.464–2.223, P < 0.001 for factor 1; OR = 1.230, 95% CI: 1.012–1.493, P = 0.037 for factor 2). Nevertheless, the similar results were not observed in females, as shown in Tables 4 and 5.
This study demonstrated the strong relationships between serum fructosamine and lipid profiles in study population, the results showed that dyslipidemia might tend to increase serum fructosamine among community-dwelling population, especially in man. Dyslipidemia characterized by higher TC, TG, LDL-C and lower HDL-C is crucial risk factor of atherosclerosis, stroke and cardiovascular disease14. Some earlier investigations have shown that dyslipidemia is associated with increased risk of cardiovascular events in patients with diabetes15. Our study observed the associations between serum fructosamine and lipid profiles in study population, suggesting serum fructosamine may provide an additional information for dyslipidemia in community-dwelling adults. There is growing evidence that modified LDL is trapped in the extracellular matrix of endothelial tissue, which is a major factor in the processes of atherosclerosis16. LDL oxidation has been regarded as an importantly initiator factor of atherosclerosis17. In addition, the interactive relationship between oxidative stress and lipid has been reported in previous studies18, and lipid peroxidation products can induce oxidative stress19. Turkdogan KA et al.18 reported that higher levels of lipid, even at an early age, might promote oxidative stress in healthy subjects. These studies mentioned above indicated a potential relationship between oxidative stress and dyslipidemia. Unfortunately, oxidative stress in fact influences protein glycation20, and there is point that oxidative stress is a key mechanism for albumin glycation in individuals without diabetes21. Thus, oxidative stress induced by dyslipidemia is a possible explanation regarding the mechanism between serum fructosamine and lipid profiles. On the other hand, a positive relation between serum fructosamine and TP levels was suggested by Shafi T et al.22. In agreement with the results, the present study observed the relationship of serum fructosamine with TP in whole participants, including males and females. Recently, albumin is served as a carrier of insulin-sensitising signal transduction, and is associated with physiological insulin sensitivity23. Historically, previous studies showed that serum fructosamine is correlated with increased insulin resistance in subjects with and without diabetes24. Obviously, these results may contribute to explain the correlation of serum fructosamine with TP. The formation of advanced glycation end products occurs by multiple processes related with reactive oxygen species25, thus, a complementary explanation to the positive correlation between serum fructosamine and age is given by the possible contribution of age-associated chronic inflammation in accelerating albumin catabolism23. However, the further pathophysiologic mechanism for these associations in the study population is needed with more investigation.
Very recently, Zaccardi F et al.26 have focused on the relationship between serum fructosamine and risk of cardiovascular in men living in communities, they found that the all-cause mortality of cardiovascular disease were not independently associated with serum fructosamine. In contrast, a cohort study provides an evidence that serum fructosamine was linked to an increase in the risk of vascular outcomes and mortality in community residents27. Similarly, higher serum fructosamine levels have been demonstrated to be associated with the morbidity of microvascular complications in non-diabetic individuals28. In earlier research, Misciagna G11 reported that non-enzymatic glycation of protein was used to predict cardiovascular events in non-diabetic subjects. In our study, we found that higher serum fructosamine levels were associated with lipid metabolism disorders in men, which indicates serum fructosamine may predict an increased risk of cardiovascular disease in men. This contradiction may be explained by following points: First, the differences derived from the heterogeneity of populations may be an important confounder in resulting in the problem. Moreover, diet style in different regions and populations may influence metabolic profiles, which may be related to the presence of cardiovascular disease in general population29. Finally, the different duration of follow-up possibly leads to the differences between these outcomes in various studies.
In the current study, we should acknowledge, however, several limitations and strengths. First, the lack of evidence linking serum fructosamine to long-term outcomes of cardiovascular disease was a major limit. Second, a relationship between glycosylated hemoglobin and lipid profiles was not assessed in the present study. Third, only single measures of laboratory parameters were carried out in our laboratory. Finally, our study only included healthy subjects, so that the conclusions may be limited by the extrapolation of results in hospitalized patients. In our study, dyslipidemia tends to contribute to increased serum fructosamine concentrations in study population, suggesting that elevated serum fructosamine may herald an increased risk of cardiovascular disease among community-dwelling adults, especially in males.
Available from: http://www.who.int/healthinfo/globalburden disease/en/ [accessed 01.07.14].
Zhang, Y., Hu, G., Yuan, Z. & Chen, L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2diabetes:a systematic review and meta-analysis. PLoS One 7, e42551 (2012).
George, J. et al. How Does Cardiovascular Disease First Present in Women and Men? Incidence of 12 Cardiovascular Diseasesin a Contemporary Cohort of 1,937, 360 People. Circulation. 132, 1320–1328 (2015).
Armbruster, D. A. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem. 33, 2153e63 (1987).
Peng, Y. F. et al. Association between Serum Fructosamine and Kidney function in Nondiabetic Individuals without ChronicKidney Disease. Med Sci Monit. 21, 1996–1999 (2015).
Nichols, T. C. et al. Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet. PLoS One 10, e0132302 (2015).
Selvin, E., Francis, L. M. & Ballantyne, C. M. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. 34, 960e7 (2011).
Gul, A. Influence of Fructose Concentration on Myocardial Infarction in Senile Diabetic and Nondiabetic Patients. Exp Clin Endocrinol Diabetes. 117, 605–609 (2009).
Shafi, T. et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. DiabetesCare. 36, 1522–1533 (2013).
Mittman, N. et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int Suppl. 117, S41–S45 (2010).
Misciagna, G., De, Michele, G. & Trevisan, M. Non enzymatic glycated proteins in the blood and cardiovascular disease. Curr Pharm Des. 13, 3688–3695 (2007).
Browner, W. S., Pressman, A. R., Lui, L. Y. & Cummings, S. R. Association between serum fructosamine and mortality in elderly women: the study of osteoporotic fractures. Am J Epidemiol. 149, 471–475 (1999).
Dobiasova, M. Atherogenic index of plasma [log(triglycerides//HDL-cholesterol)]: theoretical and practical implications. Clin Chem. 50, 1113–1115 (2004).
Betteridge, D. J. Lipid control in patients with diabetes mellitus. Nat Rev Cardiol. 8, 278–290 (2011).
Ginsberg, H. N. & Callum, P. R. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 4, 113–119 (2009).
Makita, T., Tanaka, A., Nakano, T., Nakajima, K. & Numano, F. Importance of glycation in the acceleration of low density lipoprotein (LDL) uptake into macrophages in patients with DM. Int Angiol. 18, 149–153 (1999).
Doi, H. et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation. 102, 670–676 (2000).
Turkdogan, K. A. et al. Association between oxidative stress index and serum lipid levels in healthy young adults. J Pak Med Assoc. 64, 379–381 (2014).
Noguchi, N. Role of Oxidative Stress in Adaptive Responses in Special Reference to Atherogenesis. J Clin Biochem Nutr. 43, 131–138 (2008).
Selvaraj, N., Bobby, Z., Das, A. K., Ramesh, R. & Koner, B. C. An evaluation of level of oxidative stress and protein glycation in nondiabetic undialyzed chronic renal failure patients. Clin Chim Acta. 324, 45–50 (2002).
Mueller, S., Riedel, H. D. & Stremmel, W. Determination of catalase activity at physiological hydrogen peroxide concentrations. Anal Biochem. 245, 55–60 (1997).
Shafi, T. et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care. 36, 1522–1533 (2013).
Ribeiro, R. T., Macedo, M. P. & Raposo., J. F. HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions. Curr Diabetes Rev. 12, 14–19 (2016).
Zaccardi, F. et al. Serum fructosamine and risk of type 2 diabetes mellitus among middle-age Finnish men: a 23-year population-based prospective study. Acta Diabetologica. 52, 161–166 (2015).
Adisakwattana, S., Thilavech, T. & Chusak, C. Mesona Chinensis Benth extract prevents AGE formation and protein oxidation against fructose-induced protein glycation in vitro. BMC Complement Altern Med. 7, 130–135 (2014).
Zaccardi, F., Kurl, S., Pitocco, D., Ronkainen, K. & Laukkanen, J. A. Serum fructosaminevand risk of cardiovascular and all-cause mortality:a 24-year prospective population-basedstudy. Nutr Metab Cardiovasc Dis. 25, 236–241 (2015).
Selvin, E. et al. Fructosamine and Glycated Albumin and the Risk of Cardiovascular Outcomes and Death. Circulation. 132, 269–277 (2015).
Selvin, E. et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. 34, 960e7 (2011).
Schmidt, J. A. et al. Metabolic profiles of male meat eaters, fish eaters, vegetarians, and vegans from the EPIC-Oxford cohort. Am J Clin Nutr. 102, 1518–1526 (2015).
This study was supported by the National Natural Science Foundation (No. 81560552).
The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Peng, Y., Wei, Y. The relationships between serum fructosamine concentrations and lipid profiles in community-dwelling adults. Sci Rep 7, 6886 (2017). https://doi.org/10.1038/s41598-017-07287-5
Supplemental selenium and coenzyme Q10 reduce glycation along with cardiovascular mortality in an elderly population with low selenium status – A four-year, prospective, randomised, double-blind placebo-controlled trial
Journal of Trace Elements in Medicine and Biology (2020)
New modified Friedewald formulae for estimating low-density lipoprotein cholesterol according to triglyceride levels: extraction and validation